title: How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Ferrero
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Cerrano
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Crisà
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Aguzzi
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Giai
authors.affiliation: Haematology Division, Università degli Studi di Torino, Turin, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate
keywords: chronic myeloid leukaemia; imatinib discontinuation; treatment cessation; tyrosine kinase inhibitor